Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2025 Apr 30;19(4):e0013014. doi: 10.1371/journal.pntd.0013014

Vector competence for Oropouche virus: A systematic review of pre-2024 experiments

Emily N Gallichotte 1,*, Gregory D Ebel 1, Colin J Carlson 2,*
Editor: Olaf Horstick3
PMCID: PMC12043118  PMID: 40305476

Abstract

The 2023–24 epidemic of Oropouche fever in the Americas and the associated ongoing outbreak in Cuba suggests a potential state shift in the epidemiology of the disease, raising questions about which vectors are driving transmission. In this study, we conduct a systematic review of vector competence experiments with Oropouche virus (OROV, Orthobunyavirus) that were published prior to the 2023–24 epidemic season. Only seven studies were published by September 2024, highlighting the chronic neglect that Oropouche virus (like many other orthobunyaviruses) has been subjected to since its discovery in 1954. Two species of midge (Culicoides paraensis and C. sonorensis) consistently demonstrate a high competence to transmit OROV (~30%), while mosquitoes (including both Aedes and Culex spp.) exhibited an infection rate consistently below ~20%, and showed limited OROV transmission. Further research is needed to establish which vectors are involved in the ongoing outbreak in Cuba, and whether local vectors and wildlife communities create any risk of establishment in non-endemic regions.

Summary

Oropouche virus has recently become an urgent threat to public health in Central and South America. OROV is mainly transmitted by biting midges; however, some public health agencies and scientific sources note that some mosquito species transmit the virus. We conducted a systematic review of literature prior to the current epidemic, and identified seven studies that experimentally tested the ability of vectors to become infected with, and transmit OROV (i.e., that assessed their vector competence). These studies have consistently found that biting midges become infected at higher rates than mosquitoes, which rarely transmit the virus. It is unclear which vectors are responsible for transmitting OROV in the current outbreak. Existing published data support the observation that biting midges are likely to be significant vectors compared to mosquitoes, which are comparatively incompetent. However, increased vector surveillance and pathogen testing, and additional vector competence experiments using current OROV strains, are urgently needed.

Introduction

Oropouche virus (OROV) is a Simbu serogroup orthobunyavirus endemic to South America and parts of the Caribbean. Historically, OROV has been neglected compared to other arboviral diseases, such as yellow fever, dengue, chikungunya, or Zika. However, an ongoing epidemic of Oropouche fever has brought new attention to the virus. In the first seven months of 2024, there were more than 8,000 cases across the Americas, mostly concentrated in Brazil; at the time of writing, a second epidemic wave is ongoing in Cuba, with over 11,000 suspected cases. The scale of this outbreak may be connected to evolutionary changes in the pathogen: recent genetic analyses revealed that the OROV lineage currently circulating in Brazil is a novel reassortant containing M segment from viruses detected in the eastern Amazon from 2009-2018, and L and S segments from viruses detected in Peru from 2008-2021 [1]. In vitro characterization of the novel reassortant virus recently demonstrated that it replicates to higher levels than the prototypic strain in mammalian cells, and is less sensitive to neutralization by human OROV immune sera collected prior to 2016 [2]. This reassortment event may also result in changes in the clinical presentation of Oropouche fever. Prior to 2024, symptoms were generally considered similar to other febrile illnesses, and no deaths had been reported [3]; in the 2024 outbreak, however, two deaths caused by OROV were reported in healthy young women, and there have been multiple reports of miscarriage, fetal deaths, and microcephaly associated with OROV infection [4].

Surprisingly little is known about the vectors involved in the current epidemic. Current evidence suggests that, unlike many other arthropod-borne orthobunyaviruses, OROV is primarily transmitted by culicoid midges (Ceratopogoidae: Culicoides) rather than mosquitoes or ticks [5]. C. paraensis are considered the principal vector of epidemic urban OROV transmission due to their high abundance in locations of previous OROV outbreaks, and OROV isolation from C. paraensis multiple times during a 1975 outbreak in Brazil [68]. Culicoides are efficient vectors for many arboviruses, including other Simbu serogroup orthobunyaviruses in South America [9]. They feed on a variety of vertebrates, and three-toed sloths, birds, and non-human primates (capuchin and howler-monkeys) are thought to be the primary hosts of sylvatic OROV [10].

When OROV was first detected in 1955 in Trinidad & Tobago, over 700 mosquitoes (Aedes, Wyeomyias, Psorophora, Mansonia, Culex, Anopheles, Haemogogous, and other unidentified sabethines) were collected from the same area as the infected patient, but OROV was only detected in Coquillettidia venezuelensis (referred to as Mansonia venezuelensis in the paper) [11]. In 1961, OROV was isolated from a pool of Aedes serratus in Brazil [12]. Because Cq. venezuelensis and Ae. serratus are hematophagous mosquitoes that inhabit sylvatic environments, they were suggested as potential sylvatic vectors. Cx. quinquefasciatus have also been proposed as a secondary, urban, anthropophilic vector because OROV has been isolated from them multiple times [7,13]. However, in all instances of virus isolation from mosquitoes, the resulting detection rates were very low, suggesting poor susceptibility of the vector to infection. Overall, these suggest that many blood-feeding arthropods are exposed to the virus in nature, but mosquitoes may not be meaningfully involved in transmission. The scale of the current epidemic, particularly in Cuba, has prompted speculation about a potential shift to mosquito vectors, especially since no Culicoides species have been reported there, but so far no observational data supports this idea [14,15].

To define the extent and outcomes of previously published vector competence experiments using OROV, we developed a standardized dataset of all pre-2024 records of vector competence experiments that studied OROV, following a previously-developed data standard [16]. The data standard contains fields for vector, virus, exposure, experimental and infection conditions, and experimental outcomes, allowing us to standardize variables, making it easier to compare across studies. Despite the large number of outbreaks over the last 50 years, there is significant uncertainty regarding which vectors are responsible for OROV transmission, including in the current epidemic. Because the virus is spreading to locations where it has not previously been detected (e.g., Cuba [17]), and could continue to spread to new locations (e.g., the United States), it is critical to understand transmission risk posed by a wide range of potential vectors. Unfortunately, we found that before 2024 there was limited experimental research testing the ability of different vectors to become infected with, and transmit OROV. The small number of studies that have been conducted demonstrate that Culex spp. can infrequently be infected with OROV, but transmit virus at low rates compared to Culicoides midges. It thus seems unlikely that mosquitoes have been a major vector of OROV thus far.

Materials and methods

Systematic search

A systematic search was conducted on September 17, 2024 on PubMed using the search term “Oropouche virus” (no other databases were used, nor were additional spellings or abbreviations included as search terms). No filters or limits were used. The search returned 168 publications, which were imported into Rayyan for manual screening [18]. Exclusion criteria included: reviews, news articles, commentaries, surveillance studies, experimental studies in systems other than vectors (e.g., cells, mice, etc.), etc.). The following inclusion criteria were required: full text available in English; experimental OROV infections in vectors (mosquitoes or midges), and raw data must be available (e.g., number of individual vectors positive and total number tested, not derived rates) (no papers were identified that did not have raw data available). A single reviewer screened all publications. Two additional publications were identified from citation searching. One publication was frequently cited in multiple reviews stating susceptibility of multiple vectors to OROV infection [11]. This paper was identified in our original search, but had been excluded because there was no mention of experimental vector competence in the title or abstract. A second publication did not show up in our original search, but was also identified due to frequent reference in other publications [19]. There were seven publications that met all criteria and were used in our analyses.

Data collection

Information was extracted from publications into a standardized template, following a previously-published minimum data and metadata standard [16]. Data sections include information on vectors, viruses, experimental conditions, infection conditions, and infection outcomes (specifically sample type tested, assay used to detect infection, number tested, and number positive). Information not provided in publications were left blank, and no assumptions were made about any missing or unclear information. Experiments evaluating the ability of OROV to be mechanically transmitted by vectors were not included. Authors of de Mendonça et al. [20] were contacted for the vector origin year which was provided. Risk of bias assessment, effect measures, reporting bias assessment and certainty assessment were not determined.

Data analysis and statistics

All data were analyzed in GraphPad Prism Version 10.2.3.

Results

Systematic search and selection process

We performed a systematic review using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) reporting guidelines. A total of 168 publications were retrieved from PubMed (see Methods for search criteria) and screened for eligibility. Abstracts were reviewed, and only five met all eligibility criteria [2024]. Two additional publications were identified from citation searching, which met all eligibility criteria, and were included in the final sample (Fig 1) [11,19]. Experimental data were extracted from published studies into a previously described template allowing for comparisons and analyses [16].

Fig 1. PRISMA flow diagram of search according to PRISMA 2020 strategy [36].

Fig 1

Summary of included studies

The seven eligible studies were published in 1961, 1981, 1982, 1987, 1991, and 2021 (n = 2 studies in 2021) (Fig 2a). Shortly after the first OROV outbreak in Trinidad in 1954, the first experimental vector competence study was published. OROV subsequently caused outbreaks in many countries in Central and South America, with many in Brazil and Peru (Fig 2a). Minimal experimental details were available and uncommon methods were used in Anderson et al. [11], making comparisons across studies challenging, so results from this study are discussed separately later. The six remaining studies included multiple Aedes, Culex, and Culicoides species, with multiple studies comparing different vectors (Fig 2b).

Fig 2. OROV outbreaks and experimental vector competence publications.

Fig 2

a) Timeline of OROV outbreaks in countries in the Caribbean and Central and South America, modified from Tilston-Lunel, 2024 [37]. Experimental vector competence publications from PRISMA review are shown by publication date. b) Vector species (Aedes, Culex and Culicoides spp.) tested for each of the six papers identified through the PRISMA search (Fig 1). [1924].

Vectors used in experimental studies

Vectors used in studies were originally collected throughout the Americas and in Thailand, and in some studies, multiple species were collected from the same location (Fig 3a and 3b). Some vectors were collected from the field within a few years of study publication, however other colonies (e.g., Cx. tarsalis from McGregor et al. [23]), were colonized 60 + years prior to experimental infections and publications (Fig 3c).

Fig 3. Experimental vector origin location and collection year.

Fig 3

a) Map and b) table of the origin of each vector used in experimental vector competence publications. World map created in BioRender. c) The vector collection year of each colony/strain of species (line) relative to the corresponding publication year (circle/hexagon). Vectors without a collection year stated in the publication are shown as hexagons without a corresponding line. *Collection year of vectors used in de Mendonça et al. [20] were provided directly by the authors.

A total of 2,408 individual vectors were tested in vector competence experiments; 28% Aedes spp., 55% Culex spp. and 16% Culicoides spp. (Fig 4a). Vectors were exposed to OROV via feeding on a live animal, artificial bloodmeal, and intrathoracic injection (Fig 4a). Of those fed on live animals, the majority were fed on infected hamsters, with a smaller proportion fed on AG129 mice, and humans (Fig 4b). Vectors were exposed to a large range of OROV infectious titers, quantified using multiple techniques, ranging from 5.2 to 9.9 log10 SMLD50/mL (Fig 4c).

Fig 4. Vectors and OROV used in vector competence experiments.

Fig 4

a) For each vector species, the total number of individuals tested, and their virus exposure method (e.g., live animal, artificial bloodmeal, intrathoracic injection). b) Of vectors exposed via a live animal, the number of individuals tested by the species of animal they were fed on. c) OROV titer by the vector exposure method and virus quantification assay (log10 transformed plaque forming units (PFU), plaque forming units per milliliter (PFU/mL), or suckling mouse lethal dose 50 per milliliter (SMLD50/mL)). OROV titers used in experiments show a black hash mark, with a gray line connecting the range. In one experiment of vectors fed on a live animal, virus was quantified as 5.2 log10 SMLD50/mL or lower (denoted as a dotted gray line).

Vector competence of mosquitoes and midges infected with OROV

Infection rates were calculated for all studies, with time points, virus quantification method, vector sample, and other variables combined. Of vectors infected via a live animal or artificial bloodmeal, only Culicoides (both C. paraensis and C. sonorensis) had infection rates >20% (Fig 5a). This was dose-dependent, as no C. paraensis exposed to OROV ≤5.2 log10 SMLD50/mL were infected. Conversely, while Aedes and Culex spp. injected with OROV were efficiently infected, those exposed via live animal and artificial bloodmeal had infection rates <20% regardless of virus titer (Fig 5a). Despite a range of infection rates, when comparing individual experiments, Culicoides spp. had higher average infection rates than all mosquito species tested (Fig 5b). Similar trends are seen with dissemination rates, C. sonorensis have higher rates of dissemination compared to both Aedes and Culex spp. (Fig 5c).

Fig 5. OROV infection, dissemination and transmission rates in mosquitoes and midges.

Fig 5

Infection, dissemination and transmission rates (percentage of infected vectors of the total tested) for each experiment, by vector spp., a) exposure method and virus titer (all virus quantification assays on the same axis). a) Experiments where virus concentration was unknown are plotted at the far right of the x-axis (“?”) (n = 4 Ae. aegypti, n = 2 Ae. albopictus, n = 2 Cx. quinquefasciatus). In three experiments feeding C. parensis on live animals, the virus titer was provided as a range (e.g., 5.3-6.3 log10 SMLD50/mL), shown with a red line with symbol plotted at the average titer. b) Infection, c) dissemination and d) transmission results for all experiments by vector spp. and exposure method. Each experiment is shown as a circle, with averages for the species shown as a diamond. Infection rates (a, b) were measured via vector body or abdomen (artificial bloodmeal and live animal exposure), or head and thorax (intrathoracic injection). c) Dissemination rates were measured via legs, or head and thorax (artificial bloodmeal and live animal), or abdomen (intrathoracic injection). d) Left panel - transmission rates were measured via the number of vector saliva samples out of total saliva samples measured. Right panel - transmission rates were measured via the number of virus positive recipient animals fed on by vectors, out of the total of recipient animals tested. In all graphs, symbols show mean, with error bars showing 95% Wilson/Brown confidence intervals.

Across studies, transmission was evaluated two ways: the detection of OROV in expectorated vector saliva, and detection of infection (virus or seroconversion) in naïve animals fed on by infected vectors (Fig 5d). C. sonorensis had significantly higher rates of OROV in saliva compared to Cx. tarsalis and Cx. quinquefasciatus (Fig 5d). Similarly, C. paraensis had higher rates of OROV transmission to naïve animals compared to Ae. albopictus and Cx. quinquefasciatus, however the confidence intervals are much larger due to the lower number of animals tested as compared to vector saliva (Fig 5d).

The first study evaluated OROV infection and transmission in parenterally inoculated Ae. scapularis, Ae. serratus, Cx. quinquefasciatus (referred to as Cx. fatigans in the paper), and Psorophora ferox (Fig 6) [11]. Despite small group sizes (n = 7, 4, 4, 5, respectively), two weeks after inoculation, all species became infected, with lowest infection rates in P. ferox (Fig 6a). To evaluate transmission, two weeks after inoculation, mosquitoes were fed on 2-day old mice. The mice were immediately blended in diluent, which was then intracranially injected into infant mice, and disease was monitored. While the number of recipient mice exposed and tested was not stated, no transmission occurred (Fig 6b).

Fig 6. No OROV transmission in parenterally inoculated mosquitoes.

Fig 6

a) Infection rates (number infected vectors of the total number tested) for each mosquito species. Mosquito samples (e.g., body, thorax) tested to evaluate infection are unknown. Symbols show mean, with error bars showing 95% Wilson/Brown confidence intervals. b) Number of recipient animals testing positive for OROV after i.c. injection of mouse homogenate immediately after being fed on by OROV-inoculated mosquitoes.

Discussion

Our systematic review revealed that, in the six decades between the discovery of Oropouche virus and the 2023–24 epidemic in the Americas, only seven vector competence studies were published. Even accounting for the possibility that more experiments were conducted but never published, our findings reveal that OROV has been subject to chronic neglect – a pattern that is true more broadly of most orthobunyaviruses, particularly compared to well-studied flaviviruses (e.g., yellow fever virus and dengue virus) and alphaviruses (e.g., chikungunya virus and Mayaro virus) [25]. Nevertheless, the seven studies we identified – and the nine arthropod species they examined – provide a useful starting point for establishing the vectors involved in sylvatic and urban OROV transmission, as well as the basic biology of OROV-vector interactions.

Despite variation in study design, methods, and materials (e.g., geographic origin of vectors or time since collection from the field), results consistently showed that Aedes and Culex mosquitoes rarely become infected with OROV following an infectious bloodmeal, and have a limited ability to transmit the virus. Intrathoracic injections, which bypass the initial midgut infection and escape barriers and deliver virus directly into the hemocoel, revealed that OROV can replicate in mosquitoes, suggesting lack of infection following oral exposure, is likely not molecular incompatibility between the virus and vector, but instead limited ability to infect the midgut. While studies based on intrathoracic injection are useful to understand fundamental questions of virus-vector interactions, we also caution that they are not representative of natural infection and transmission risk. In nature, vectors will only be exposed to virus orally, and therefore, transmission when these barriers are bypassed (e.g., intrathoracic injection), are not relevant to transmission.

Midges (Culicoides spp.) are the primary vectors of many viruses of medical and veterinary importance, including bluetongue virus (BTV), Schmallenberg virus, and OROV-related viruses within the Simbu serogroup of the genus Orthobunyavirus [9]. However, they remain dramatically under-studied and under-surveyed in comparison to mosquitoes and ticks. Despite the limited number of publications, all experimental results support the observation that Culicoides midges are highly competent vectors for OROV. However, there are few studies experimentally evaluating midge vector competence for any virus due to challenges surrounding lab colonization and experimental manipulation of these arthropods [26]. Epidemiological evidence implicates C. parensis as the primary urban vector [7], but detection and isolation rates in wild C. paraensis pools have been low (4 positive of 31,555 tested, ~ 0.01% positivity) [6,7]. Importantly, while there are over 1,300 species of Culicoides, OROV has only been detected in C. paraensis during outbreak vector surveillance, and only two species (C. paraensis and C. sonorensis) have been experimentally tested and demonstrated to transmit OROV [7,9]. Additionally, while they are abundant globally, there is far less surveillance of Culicoides compared to other vectors (e.g., mosquitoes), leaving incomplete distribution maps, and there are no reported occurrences of any Culicoides spp. in Cuba, where OROV transmission is endemic [27]. Further research is needed to confirm which Culicoides species are actively involved in the current OROV outbreaks, or could someday pose a risk, especially in new locations.

Based on current evidence, mosquitoes are unlikely to be a primary vector of OROV in natural settings. Despite extensive efforts, OROV has rarely been isolated from mosquito vectors of other arboviruses, even during outbreaks when it has been estimated >15% of the population is infected [7]. Of > 28,000 Cx. quinquefasciatus mosquitoes tested during outbreaks over 14 years, only three have tested positive (~0.01%), including a mosquito engorged with blood caught in a hospital ward at the bedside of a viremic patient 1975 in Pará, Brazil [6,7]. Low infection and transmission rates seen in experimental vector competence studies, and incredibly low rates of virus isolation during outbreaks, suggest that Cx. quinquefasciatus are likely a comparatively poor vector for OROV. However, vector competence is only one component of vectorial capacity, which also incorporates factors such as vector density and bloodfeeding behavior [28]; therefore, a vector with low competence may still be important at maintaining and transmitting the virus in nature, as has been demonstrated with Ae. albopictus and dengue virus [29].

It remains unknown whether shifts in vector-virus interactions have contributed to the current epidemic. It is possible that genetic changes to the virus have improved vector competence, similar to what has been seen with chikungunya virus and Ae. albopictus, or West Nile virus and Culex spp. mosquitoes [3032]. New experiments should focus on establishing whether the novel reassortant is more transmissible by Culicoides midges, or can be newly maintained by common urban vectors such as Ae. aegypti or Cx. quinquefasciatus. Importantly, a recent paper using OROV isolated from a febrile patient from Cuba in 2024, demonstrated experimental infection rates in mosquitoes (Ae. albopictus, Anopheles quadrimaculatus, Cx. quinquefasciatus and Cx. pipiens) were low (<4%), and comparable to rates of mosquitoes infected with the 1955 prototypic strain (<2%), suggesting the currently circulating virus is not adapted to, nor improved at infection of and transmission by mosquitoes [33]. However, other factors could also contribute to the unusual intensity of recent and ongoing outbreaks, including climate change, urbanization, deforestation, and human mobility [10,29,34,35]. Field studies on the epidemiology and drivers of these outbreaks will be an important complement to experimental work, particularly to establish whether Oropouche virus will continue to emerge as a threat to public health in the coming decades.

Supporting information

S1 Table. Oropouche virus experimental metadata.

(XLSX)

pntd.0013014.s001.xlsx (232.6KB, xlsx)
S2 Table. PRISMA checklist.

(DOCX)

pntd.0013014.s002.docx (33.8KB, docx)

Acknowledgments

We thank Silvana de Mendonça and colleagues for providing additional data, and thank Doug Brackney and Nate Grubaugh for helpful discussion.

Data Availability

All data are publicly available on Figshare (10.6084/M9.FIGSHARE.27157029.V1; https://figshare.com/articles/dataset/Oropouche_vector_competence_data/27157029?file=49855260)

Funding Statement

This work was supported by National Science Foundation DBI 2021909, 2213854, and 2515340 (CJC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Naveca FG, Almeida TAP de, Souza V, Nascimento V, Silva D, Nascimento F, et al. Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region. Nat Med. 2024;30(12):3509–21. doi: 10.1038/s41591-024-03300-3 [DOI] [PubMed] [Google Scholar]
  • 2.Scachetti GC, Forato J, Claro IM, Hua X, Salgado BB, Vieira A, et al. Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study. Lancet Infect Dis. 2025;25(2):166–75. doi: 10.1016/S1473-3099(24)00619-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Liu BM. Epidemiological and clinical overview of the 2024 Oropouche virus disease outbreaks, an emerging/re-emerging neurotropic arboviral disease and global public health threat. J Med Virol. 2024;96(9):e29897. doi: 10.1002/jmv.29897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.The Lancet Infectious Diseases. Oropouche fever, the mysterious threat. Lancet Infect Dis. 2024;24(9):935. doi: 10.1016/S1473-3099(24)00516-4 [DOI] [PubMed] [Google Scholar]
  • 5.Elliott RM. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol. 2014;12(10):673–85. [DOI] [PubMed] [Google Scholar]
  • 6.Pinheiro FP, Travassos da Rosa AP, Travassos da Rosa JF, Bensabath G. An outbreak of Oropouche virus diease in the vicinity of santarem, para, barzil. Tropenmed Parasitol. 1976;27(2):213–23. [PubMed] [Google Scholar]
  • 7.Pinheiro FP, Travassos da Rosa AP, Travassos da Rosa JF, Ishak R, Freitas RB, Gomes ML, et al. Oropouche virus. I. A review of clinical, epidemiological, and ecological findings. Am J Trop Med Hyg. 1981;30(1):149–60. [PubMed] [Google Scholar]
  • 8.Roberts DR, et al. Oropouche virus. III. Entomological observations from three epidemics in Para, Brazil, 1975. Am J Trop Med Hyg. 1981;30(1):165–71. [PubMed] [Google Scholar]
  • 9.Sick F, et al. Culicoides Biting Midges-Underestimated Vectors for Arboviruses of Public Health and Veterinary Importance. Viruses. 2019;11(4). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zhang Y, Liu X, Wu Z, Feng S, Lu K, Zhu W, et al. Oropouche virus: A neglected global arboviral threat. Virus Res. 2024;341:199318. doi: 10.1016/j.virusres.2024.199318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Anderson CR, Spence L, Downs WG, Aitken TH. Oropouche virus: a new human disease agent from Trinidad, West Indies. Am J Trop Med Hyg. 1961;10:574–8. doi: 10.4269/ajtmh.1961.10.574 [DOI] [PubMed] [Google Scholar]
  • 12.Pinheiro FP, et al. Epidemia de vírus Oropouche em Belém. Revista de Servico Especial de Saude Publica. 1962;12:15–23. [Google Scholar]
  • 13.Cardoso BF, Serra OP, Heinen LB da S, Zuchi N, Souza VC de, Naveca FG, et al. Detection of Oropouche virus segment S in patients and inCulex quinquefasciatus in the state of Mato Grosso, Brazil. Mem Inst Oswaldo Cruz. 2015;110(6):745–54. doi: 10.1590/0074-02760150123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Castro G. This Tropical Virus Is Spreading Out of the Amazon to the US and Europe. 20 Dec 2024; Available from: https://www.wired.com/story/this-tropical-virus-is-spreading-out-of-the-amazon-to-the-us-and-europe/. [Google Scholar]
  • 15.Lenharo M. Mysterious Oropouche virus is spreading: what you should know. Nature. 2024. [DOI] [PubMed] [Google Scholar]
  • 16.Wu VY, Chen B, Christofferson R, Ebel G, Fagre AC, Gallichotte EN, et al. A minimum data standard for vector competence experiments. Sci Data. 2022;9(1):634. doi: 10.1038/s41597-022-01741-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Escobedo AA, Rodríguez-Morales AJ. Oropouche fever rears its head in Cuba: What lies beneath the surface? New Microbes New Infect. 2024;62:101460. doi: 10.1016/j.nmni.2024.101460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ouzzani M, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Smith GC, Francy DB. Laboratory studies of a Brazilian strain of Aedes albopictus as a potential vector of Mayaro and Oropouche viruses. J Am Mosq Control Assoc. 1991;7(1):89–93. [PubMed] [Google Scholar]
  • 20.de Mendonça SF, Rocha MN, Ferreira FV, Leite THJF, Amadou SCG, Sucupira PHF, et al. Evaluation of Aedes aegypti, Aedes albopictus, and Culex quinquefasciatus Mosquitoes Competence to Oropouche virus Infection. Viruses. 2021;13(5):755. doi: 10.3390/v13050755 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Pinheiro FP, Travassos da Rosa AP, Gomes ML, LeDuc JW, Hoch AL. Transmission of Oropouche virus from man to hamster by the midge Culicoides paraensis. Science. 1982;215(4537):1251–3. doi: 10.1126/science.6800036 [DOI] [PubMed] [Google Scholar]
  • 22.Hoch AL, Pinheiro FP, Roberts DR, Gomes ML. Laboratory transmission of Oropouche virus by Culex Quinquefasciatus Say. Bull Pan Am Health Organ. 1987;21(1):55–61. [PubMed] [Google Scholar]
  • 23.McGregor BL, Connelly CR, Kenney JL. Infection, Dissemination, and Transmission Potential of North American Culex quinquefasciatus, Culex tarsalis, and Culicoides sonorensis for Oropouche Virus. Viruses. 2021;13(2):226. doi: 10.3390/v13020226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Pinheiro FP, Hoch AL, Gomes ML, Roberts DR. Oropouche virus. IV. Laboratory transmission by Culicoides paraensis. Am J Trop Med Hyg. 1981;30(1):172–6. doi: 10.4269/ajtmh.1981.30.172 [DOI] [PubMed] [Google Scholar]
  • 25.Chen B, Sweeny AR, Wu VY, Christofferson RC, Ebel G, Fagre AC, et al. Exploring the Mosquito-Arbovirus Network: A Survey of Vector Competence Experiments. Am J Trop Med Hyg. 2023;108(5):987–94. doi: 10.4269/ajtmh.22-0511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Carpenter S, Veronesi E, Mullens B, Venter G. Vector competence of Culicoides for arboviruses: three major periods of research, their influence on current studies and future directions. Rev Sci Tech. 2015;34(1):97–112. doi: 10.20506/rst.34.1.2347 [DOI] [PubMed] [Google Scholar]
  • 27.Mellor PS, Boorman J, Baylis M. Culicoides biting midges: their role as arbovirus vectors. Annu Rev Entomol. 2000;45:307–40. doi: 10.1146/annurev.ento.45.1.307 [DOI] [PubMed] [Google Scholar]
  • 28.Kramer LD, Ciota AT. Dissecting vectorial capacity for mosquito-borne viruses. Curr Opin Virol. 2015;15:112–8. doi: 10.1016/j.coviro.2015.10.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Garcia-Rejon JE, et al. An Updated Review of the Invasive Aedes albopictus in the Americas; Geographical Distribution, Host Feeding Patterns, Arbovirus Infection, and the Potential for Vertical Transmission of Dengue Virus. Insects. 2021;12(11). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ebel GD, et al. Genetic and phenotypic variation of West Nile virus in New York, 2000-2003. Am J Trop Med Hyg. 2004;71(4):493–500. [PubMed] [Google Scholar]
  • 31.Moudy RM, Meola MA, Morin L-LL, Ebel GD, Kramer LD. A newly emergent genotype of West Nile virus is transmitted earlier and more efficiently by Culex mosquitoes. Am J Trop Med Hyg. 2007;77(2):365–70. doi: 10.4269/ajtmh.2007.77.365 [DOI] [PubMed] [Google Scholar]
  • 32.Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 2007;3(12):e201. doi: 10.1371/journal.ppat.0030201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Payne AF, et al. Lack of Competence of US Mosquito Species for Circulating Oropouche Virus. Emerg Infect Dis. 2025;31(3):619–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Gräf T, Delatorre E, do Nascimento Ferreira C, Rossi A, Santos HGG, Pizzato BR, et al. Expansion of Oropouche virus in non-endemic Brazilian regions: analysis of genomic characterisation and ecological drivers. Lancet Infect Dis. 2025;25(4):379–89. doi: 10.1016/S1473-3099(24)00687-X [DOI] [PubMed] [Google Scholar]
  • 35.Taglialegna A. Re-emergence of Oropouche virus. Nat Rev Microbiol. 2024;22(12):740. doi: 10.1038/s41579-024-01118-x [DOI] [PubMed] [Google Scholar]
  • 36.Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10(1):39. doi: 10.1186/s13643-020-01542-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tilston-Lunel NL. Oropouche Virus: An Emerging Orthobunyavirus. J Gen Virol. 2024;105(9). [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0013014.r002

Decision Letter 0

Olaf Horstick

29 Jan 2025

PNTD-D-24-01594Vector competence for Oropouche virus: a systematic review of pre-2024 experimentsPLOS Neglected Tropical Diseases Dear Dr. Gallichotte, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within 30 days Mar 30 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers '. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes '.* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript '. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Olaf Horstick, FFPH(UK)Academic EditorPLOS Neglected Tropical Diseases Andrea MarziSection EditorPLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

Journal Requirements:

1) Please ensure that the CRediT author contributions listed for every co-author are completed accurately and in full.

At this stage, the following Authors/Authors require contributions: Emily Gallichotte, Gregory D Ebel, and Colin J Carlson. Please ensure that the full contributions of each author are acknowledged in the "Add/Edit/Remove Authors" section of our submission form.

The list of CRediT author contributions may be found here: https://journals.plos.org/plosntds/s/authorship#loc-author-contributions

2) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines: 

https://journals.plos.org/plosntds/s/figures

3) Some material included in your submission may be copyrighted. According to PLOSu2019s copyright policy, authors who use figures or other material (e.g., graphics, clipart, maps) from another author or copyright holder must demonstrate or obtain permission to publish this material under the Creative Commons Attribution 4.0 International (CC BY 4.0) License used by PLOS journals. Please closely review the details of PLOSu2019s copyright requirements here: PLOS Licenses and Copyright. If you need to request permissions from a copyright holder, you may use PLOS's Copyright Content Permission form.

Please respond directly to this email and provide any known details concerning your material's license terms and permissions required for reuse, even if you have not yet obtained copyright permissions or are unsure of your material's copyright compatibility. Once you have responded and addressed all other outstanding technical requirements, you may resubmit your manuscript within Editorial Manager. 

Potential Copyright Issues:

i) Figure 3a. Please (a) provide a direct link to the base layer of the map (i.e., the country or region border shape) and ensure this is also included in the figure legend; and (b) provide a link to the terms of use / license information for the base layer image or shapefile. We cannot publish proprietary or copyrighted maps (e.g. Google Maps, Mapquest) and the terms of use for your map base layer must be compatible with our CC BY 4.0 license.

Note: if you created the map in a software program like R or ArcGIS, please locate and indicate the source of the basemap shapefile onto which data has been plotted.

If your map was obtained from a copyrighted source please amend the figure so that the base map used is from an openly available source. Alternatively, please provide explicit written permission from the copyright holder granting you the right to publish the material under our CC BY 4.0 license.

If you are unsure whether you can use a map or not, please do reach out and we will be able to help you. The following websites are good examples of where you can source open access or public domain maps:

* U.S. Geological Survey (USGS) - All maps are in the public domain. (http://www.usgs.gov)

* PlaniGlobe - All maps are published under a Creative Commons license so please cite u201cPlaniGlobe, http://www.planiglobe.com, CC BY 2.0u201d in the image credit after the caption. (http://www.planiglobe.com/?lang=enl)

* Natural Earth - All maps are public domain. (http://www.naturalearthdata.com/about/terms-of-use/).

4) As required by our policy on Data Availability, please ensure your manuscript or supplementary information includes the following:

- A numbered table of all studies identified in the literature search, including those that were excluded from the analyses.

- For every excluded study, the table should list the reason(s) for exclusion.

- If any of the included studies are unpublished, include a link (URL) to the primary source or detailed information about how the content can be accessed.

- A table of all data extracted from the primary research sources for the systematic review and/or meta-analysis. The table must include the following information for each study:

  - Name of data extractors and date of data extraction

  - Confirmation that the study was eligible to be included in the review.

  - All data extracted from each study for the reported systematic review and/or meta-analysis that would be needed to replicate your analyses.

  - If data or supporting information were obtained from another source (e.g. correspondence with the author of the original research article), please provide the source of data and dates on which the data/information were obtained by your research group.

  - If applicable for your analysis, a table showing the completed risk of bias and quality/certainty assessments for each study or outcome.  Please ensure this is provided for each domain or parameter assessed. For example, if you used the Cochrane risk-of-bias tool for randomized trials, provide answers to each of the signalling questions for each study. If you used GRADE to assess certainty of evidence, provide judgements about each of the quality of evidence factor. This should be provided for each outcome.

  - An explanation of how missing data were handled.

This information can be included in the main text, supplementary information, or relevant data repository. Please note that providing these underlying data is a requirement for publication in this journal, and if these data are not provided your manuscript might be rejected.

Reviewers' comments: Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: Were other search terms considered, such as simply “Oropouche” or “OROV” or other spellings?

Needing raw data available could have been a limitation – was this exclusion criteria applied to any potential publication?

Pg 4: some of the results are repeated here and should be removed (i.e., number of publications found by method). In addition, citation searching was mentioned but not described – were only included publication citations searched?

Pg 4, 98: PubMed

Reviewer #2: Review Methods are appropriate except:

PubMed was the only database used. Methodology for citation searching is not clear.

The term PRISMA is used in figures and supplemental files only.

Reference [1] is a preprint and should not be used as a basis for discussion of changes in clinical presentation.

Comment on recent genetic analyses (Lines 38-40) is based on study by Naveca et al in nature medicine (2025, "Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region") and needs to be cited.

Reviewer #3: The study methods are well designed and address the specific research objectives: to review vector competence studies for Oropouche virus.

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: No concerns

Reviewer #2: Figures mentioning PRISMA without context in the text.

Figure 2a: visualization of publication dates is not clearly labeled

Figure 4: Colors are not defined in legend. Usefulness of this figure is unclear.

Figure 4c: Use of OROV titers is unclear.

Figure 5a: Experiments where virus concentration was unknown are plotted at far right of the x-axis: The legend overlays this portion of the graph and the number of points at "?" are unclear.

Figure 6: This study is so different from the others that its inclusion is questionable. Transmission study was complicated and unclear whether its methodology was appropriate, so viability of the conclusion "No OROV transmission" is in question. Additionally, I needed to combine information from both this figure and lines 140-142 of the text to understand the study methodology utilizing the 2-day old mice. This should have been more clear in the text itself.

Line 51: Reference [7] utilizes more methodology than Culicoides abundance to incriminate midges in transmission.

Lines 47-63: This paragraph needs to contain more data on Culicoides because they have been shown to transmit.

Line 60: conclusion about low OROV prevalence in humans due to low detection rates in mosquitoes is flawed. When these urban vectors were collected in relation to human viremia, and low vector competence more reasonable.

Line 62: Where has speculation about potential vector shift been published?

Line 66: Please briefly describe the components of the data standard and how you used them.

Line 119: "range of OROV quantified" needs better clarification

Lines 140-142: Better communication about this study is needed, as reasoning and sequence of mosquito feeding, baby mouse blending, and IC injection is confusing. It is also worth noting the potential weaknesses of this paper.

Reviewer #3: Results and figures are well done.

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: No concerns

Reviewer #2: Line 158: vector instead of host

Line 158: conclusion that initial infection of midgut cells blocked OROV infection is not supported by data presented in this review. If retained, reference is needed here and presentation of methodology from this reference is needed in the review manuscript.

Lines 165-166: "Culicoides midges are highly competent..." and "few studies evaluating...competence" are conflicting statements. Suggest re-wording for clarity of intention.

Lines 169-170: Review content suggests that Culicoides are already known to actively transmit OROV. "...could someday pose a risk" is not supported and one wonders if this statement was meant for Culex.

Conclusion discusses "shift in vector-virus interactions" (Line 181), which is appropriate. However, Introduction discusses changes in clinical presentation of Oropouche fever (Lines 42-43) which has not been supported. Furthermore, this statement on lines 42-43 is based on a preprint, which should not be used to guide clinical work.

Reviewer #3: Conclusions are clear and summarise the work.

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: Abstract Lines 17-18: "risk of establishment in regions with frequent travel to..." This needs to be re-phrased to allow full thought processes about travel, vector ranges, human infections, animal infections, and spread of pathogens via human travel. At this time, it makes a lot of assumptions.

Summary Line 21: Caution in using the term "major threat" without quantifying current threat or prognosticating future continued threat.

Reviewer #3: Data presentation is excellent, clear and easy to understand. The authors have done well to visually display the different experimental conditions used in each study and the potential impact this would have on the outcomes.

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: This manuscript succinctly describes a highly important systematic review to determine the existence of vector competency studies for Oropouche virus. The analysis and interpretation are very good, and the figures are excellent.

Reviewer #2: More text discussion is needed about Culicoides as a vector, since this is currently determined to be the major vector of OROV.

Overall this review is well done and informative. Needs some refining.

Reviewer #3: This is a very well written paper that synthesizes vector competence studies. The authors have done very well summarising the different experimental methods and vector characteristics across studies which can impact the results and comparisons between experimental studies.

As one might expect, the key findings are that we don't know much about which species are potential vectors for Oropouche virus and that much more work is needed in this space. However, because this is a review of all the available studies it would be more impactful to include more information about the vectors that were experimentally competent. Many of the results and discussion were comparing the higher competence in Culicoides to mosquitoes, but aside from an introductory paragraph, I would have liked to know more about about the Culicoides species themselves that did demonstrate competence. It would be good to discuss and compare how those species differ from each other in the experimental studies, and include any other information that may be important for their vectorial capacity such as difference in their distributions, or known seasonality that might be important in the context of Oropouche? Are both of these species known to exist in Cuba, or other places that have historic or current epidemics?

Similarly I was wondering if there is any known evidence on non-human hosts of Oropouche, and if so, it would be good to include a few sentences. It is interesting to note that in L61 you suggest that many blood-feeding arthropods are infected but not all transmit - what could be infecting them with such low transmission in human outside of outbreak years? This is not specific to vector competence, but is important in the context of vectorial capacity, which is in the discussion.

Otherwise this study was excellent and the information is important for designing future studies and interventions for Oropouche virus.

Minor comments:

L14: What constitutes as high? Could you include a value from the results as was done for the mosquitoes

L59: Is this detection rate in humans or mosquitoes - both are mentioned, suggestion to be more explicit.

L141: At first this read to me that the mice were immediately blended (which was not what I expected to see in a vector study this morning), suggestion to be explicit that this is referring to the mosquitoes

L158: remove the brackets at and add another sentence here about why IT injections are not representative of natural infection and transmission risk.

L178: Could you include an example? Ae. albopictus and dengue would be a relevant one.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]Figure resubmission: While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions. Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0013014.r004

Decision Letter 1

Olaf Horstick

10 Mar 2025

PNTD-D-24-01594R1Vector competence for Oropouche virus: a systematic review of pre-2024 experimentsPLOS Neglected Tropical Diseases Dear Dr. Gallichotte, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within 30 days Apr 09 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers '. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes '. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript '. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Olaf Horstick, FFPH(UK)Academic EditorPLOS Neglected Tropical Diseases Andrea MarziSection EditorPLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

Journal Requirements:

Please ensure that the CRediT author contributions listed for every co-author are completed accurately and in full.

At this stage, the following Authors/Authors require contributions: Emily Gallichotte, Gregory D Ebel, and Colin J Carlson. Please ensure that the full contributions of each author are acknowledged in the "Add/Edit/Remove Authors" section of our submission form.

The list of CRediT author contributions may be found here: https://journals.plos.org/plosntds/s/authorship#loc-author-contributions

Reviewers' comments: Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods:

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: My concerns were mostly addressed, but the actual methods for citation searching are still missing. Were the citations of only included articles searched, or were the citations of non-included articles considered? Was it all articles in that category, or were they targeted somehow?

Reviewer #2: Manuscript is much improved and well done. Great job!

Line22: reads a bit clunky. Since citations are not needed in the Author Summary, recommend simplifying to what you would like to say.

Lines 113-114 dates appear contradictory.

Lines 146-150 is repetitive with line 117 and can be simplified. e.g., "Anderson et al (1961) evaluated OROV infection and transmission in parentally inoculated Ae. scapularis, Ae. serratus, Cx. quinquefasciatus (referred to as Cx. fatigans in the paper) and Psorophora ferox mosquitoes.

Line 154: Please briefly explain what was tested after diluent injection into infant mice

Line 170-171: "block of infection" seems a potential overstatement here. Wording "is not" also comes across strong.

Line 183: Recommend adding the word 'wild', as, "... detection and isolation rates in wild C. paraensis..."

Reviewer #3: (No Response)

Results:

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: No more concerns

Reviewer #2: Figure 3: Hexagons appear on the figure between years 1980-1985; but caption states hexagons show data without a collection year

Figure 5: Legend should apply to all graphs in this figure, not just a.

Number of pos samples out of total == Percent of animals tested

Reviewer #3: (No Response)

Conclusions:

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: No concerns

Reviewer #2: Good

Reviewer #3: (No Response)

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: Accept

Reviewer #3: (No Response)

Summary and General Comments:

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: (No Response)

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions.

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0013014.r006

Decision Letter 2

Olaf Horstick

27 Mar 2025

Dear Dr. Gallichotte,

We are pleased to inform you that your manuscript 'Vector competence for Oropouche virus: a systematic review of pre-2024 experiments' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Olaf Horstick, FFPH(UK)

Academic Editor

PLOS Neglected Tropical Diseases

Andrea Marzi

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

***********************************************************

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0013014.r007

Acceptance letter

Olaf Horstick

Dear Dr. Gallichotte,

We are delighted to inform you that your manuscript, "Vector competence for Oropouche virus: a systematic review of pre-2024 experiments," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Oropouche virus experimental metadata.

    (XLSX)

    pntd.0013014.s001.xlsx (232.6KB, xlsx)
    S2 Table. PRISMA checklist.

    (DOCX)

    pntd.0013014.s002.docx (33.8KB, docx)
    Attachment

    Submitted filename: Response to reviewers.docx

    pntd.0013014.s004.docx (25.6KB, docx)
    Attachment

    Submitted filename: Response to reviewers R2.docx

    pntd.0013014.s005.docx (20.8KB, docx)

    Data Availability Statement

    All data are publicly available on Figshare (10.6084/M9.FIGSHARE.27157029.V1; https://figshare.com/articles/dataset/Oropouche_vector_competence_data/27157029?file=49855260)


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES